Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Baolingbao Biology Co., Ltd. specializes in the production of functional carbohydrates and other biological products, primarily serving the food and pharmaceutical industries. Its competitive position is bolstered by a strong focus on R&D and proprietary technology in polysaccharide production, particularly in China and expanding into international markets.
Baolingbao generates revenue primarily through the sale of functional carbohydrates, which are used in food and pharmaceutical applications. The company benefits from strong pricing power due to its proprietary production processes and established relationships with major clients in the food and healthcare sectors.
Changes in demand for functional carbohydrates in the food and pharmaceutical industries
Regulatory changes affecting the biotechnology sector in China
Fluctuations in raw material prices impacting production costs
Expansion into international markets, particularly in Europe and North America
Regulatory changes that could impact product approvals and market access
Technological disruption from new entrants in the biotechnology space
Increased competition from domestic and international biotechnology firms
Price competition leading to margin compression
Low liquidity risk due to a current ratio of 1.79
Potential risks associated with R&D investments not yielding expected returns
moderate - The biotechnology sector is somewhat insulated from economic downturns, but demand for products can be affected by consumer spending and healthcare budgets.
Interest rates can impact Baolingbao's financing costs for R&D and expansion projects, potentially affecting profitability and valuation multiples.
minimal - The company has a low debt/equity ratio of 0.09, indicating limited reliance on credit.
growth - Investors looking for exposure to the expanding biotechnology sector and innovative product offerings.
moderate - The stock has experienced significant fluctuations, with a 1-year return of -25.1%, indicating potential volatility.
